Widely studied in >4000 patients1
In each of the three 2-week pivotal trials in patients 12 years and older, incidence and types of adverse reactions were comparable across all treatment groups (N=3411).1
Dymista: Adverse reactions occurring with ≥2% incidence and more frequently than with placebo were dysgeusia (4%), epistaxis (2%), and headache (2%).1 The overall incidence of adverse reactions with Dymista was 16%.1
The most frequently reported adverse reactions (≥2%) with Dymista were headache, pyrexia, cough, nasal congestion, rhinitis, dysgeusia, viral infection, upper respiratory tract infection, pharyngitis, pain, diarrhea, and epistaxis.1
Reference: 1.Dymista [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc., a Viatris Company; 2021.